EIGRQ — Eiger Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
U.S. STOCKS ON THE MOVE-Apple, MGM Resorts International, Madrigal
U.S. STOCKS ON THE MOVE-Akili, Navios Maritime Holdings, Madrigal
U.S. STOCKS ON THE MOVE-Rocket Lab, Rocket Pharma, Moderna
Eiger BioPharma down as co to scrap hepatitis drug study over safety concerns
Brief: Eiger To Discontinue Phase 3 Limt-2 Trial Of Peginterferon Lambda In Patients With Chronic Hepatitis Delta
Eiger to discontinue hepatitis drug study over safety concerns (updated)
Eiger to discontinue hepatitis drug study
Brief: Eiger BioPharmaceuticals Q2 product revenue USD 4.393 million
Eiger BioPharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Eiger Biopharmaceuticals Inc Received Notice Of Delisting From Nasdaq
U.S. RESEARCH ROUNDUP- Carnival, Nike, Paychex
Brief: David Apelian Takes Helm As CEO at Eiger Biopharmaceuticals
Brief: AnGes: Files For Japan Approval Of Premature Aging Treatment Zokinvy
Brief: Eiger Biopharmaceuticals Reports First Quarter Loss Of $0.52 Per Share
Eiger BioPharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Eiger BioPharmaceuticals Q1 product revenue USD 4.118 million